Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36967133/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Discussion: The RCTs investigating the effects of the SGLT2 inhibitors found robust results on significant reductions in three-point MACE (MACE-3), HHF, as well as renal function in patients with HF across the range of phenotypes according to LVEF (HFrEF, HFmrEF, and HFpEF). Additionally, a meta-analytic effect of AF as one of the adverse...
Share
Heart Failure and Diabetes: Clinical significance and epidemiology of this two-way association - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36949650/
People with type 2 diabetes (T2DM) and those with pre-diabetes have an increased risk of heart failure (HF). Longer duration of T2DM correlates with a greater risk of HF, but...
Conclusions/Relevance: Most recently the SGLT-2 receptor blockers have shown efficacy in both HFrEF and HFpEF. The only other oral or injectable diabetes agent shown to improve outcomes in both is metformin.
Share
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
Source : https://www.sciencedirect.com/science/article/abs/pii/S0735109723003686?via=ihub
Available online 21 March 2023 Author links open overlay panel Vandana Sachdev MD (Chair) ∗ † , Kavita Sharma MD (Vice Chair) , , , , , , , ,...
Conclusions/Relevance: Critical gaps in implementation of exercise-based therapies for patients with HFpEF, including exercise setting, training modalities, combinations with other strategies such as diet and medications, long-term adherence, incorporation of innovative and more accessible delivery methods, and management of recently...
Share
Galectin-3 and HFpEF: Clarifying an Emerging Relationship
Source : https://www.eurekaselect.com/article/130278
Introduction: HFpEF is a leading cause of death whose burden is projected to increase in the coming decades. The aim of this paper is to interrogate the relationship between levels...
Conclusion: Given the paucity of effective therapeutics for HFpEF, galectin-3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.
Share
The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
Cardiovascular disease (CVD) is the leading cause of mortality in patients with type 2 diabetes mellitus (DM) worldwide. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were initially developed for treating patients with type...
Conclusions/Relevance: The participants included in this study had various basal metabolic indices, ages, glomerular filtration rates, and diabetic status characteristics. Although these patients were quite different, after the administration of SGLT2i, the studies showed a beneficial effect in reducing CVD mortality and morbidity in patients...
Share